Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A double-blind, prospective, randomized study assessing the efficacy and safety of evenamide (15, 30 mg bid) as add-on in TRS patients not responding to their current atypical antipsychotic

Next Previous
Search
Trial Profile

A double-blind, prospective, randomized study assessing the efficacy and safety of evenamide (15, 30 mg bid) as add-on in TRS patients not responding to their current atypical antipsychotic

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 21 Dec 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Evenamide (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use

    • Most Recent Events

    • 13 Dec 2024 According to a Newron Pharmaceuticals media release, under license agreement between EA pharma and Newron, Newron will receive up to a maximum total of euro117 million from EA Pharma, including an upfront payment of euro 44 million, financial contributions to its upcoming Phase III one-year study to be performed outside of the licensed territories.
    • 13 Dec 2024 According to a Newron Pharmaceuticals media release, this trial is expected to initiate in H1 2025.
    • 04 Jan 2024 According to a Newron Pharmaceuticals media release, 1-year findings from study 014/015 support the initiation of this Phase III trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top